Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
Tsunehiro Yasuda,Herman K. Gold,John T. Fallon,Robert C. Leinbach,J L Guerrero,L E Scudder,Michito Kanke,D Shealy,M J Ross,D. Collen +9 more
TL;DR: It is concluded that the monoclonal antibody is very effective in preventing reocclusion after successful thrombolysis of occluded coronary arteries with rt-PA.
read more
Abstract: Localized thrombosis was produced in the left anterior descending (LAD) coronary artery of open chest dogs by constricting a segment so as to produce greater than 90% stenosis (reducing blood flow to 40 +/- 10% of baseline), and placing a thrombus in the segment immediately proximal to the stenosis by inducing endothelial cell injury and instilling a mixture of blood and thrombin. Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) at a rate of 15-30 micrograms/kg per min for 30 or 60 min in eight dogs induced coronary artery reperfusion within 23 +/- 7 min (mean +/- SD), but reocclusion occurred despite heparin anticoagulation in all but one of these dogs within 7 +/- 5 min. Intravenous injection of 0.8 mg/kg of the F(ab')2 fragment of a monoclonal antibody (7E3) directed against the platelet GPIIb/IIIa receptor, prevented reocclusion in 10/10 dogs during an observation period of 2 h (P less than 0.001 vs. rt-PA alone). The antibody abolished ADP-induced platelet aggregation and markedly prolonged the bleeding time. Intravenous aspirin or dipyridamole prevented reocclusion for 1 h or more in only 2/7 and 1/6 dogs, respectively. We conclude that the monoclonal antibody is very effective in preventing reocclusion after successful thrombolysis of occluded coronary arteries with rt-PA.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.
TL;DR: Platelets have a key role in atherosclerosis, thrombosis, and acute coronary syndromes and therapeutic manipulation of platelet function has focused principally on the use of aspirin.
826
Abciximab Facilitates the Rate and Extent of Thrombolysis Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial
Elliott M. Antman,Robert P. Giugliano,C. Michael Gibson,Carolyn H. McCabe,P Coussement,Neal S. Kleiman,Alec Vahanian,A.A.Jennifer Adgey,Ian B. A. Menown,Hans J. Rupprecht,R. Van der Wieken,John Ducas,Joel C Scherer,Keaven M. Anderson,Frans Van de Werf,Eugene Braunwald +15 more
TL;DR: Abciximab facilitates the rate and extent of thrombolysis, producing early, marked increases in TIMI 3 flow when combined with half the usual dose of alteplase, and substantial reductions in heparin dosing may reduce the risk of bleeding even further.
721
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
James E. Tcheng,Stephen G. Ellis,Barry S. George,Dean J. Kereiakes,Neal S. Kleiman,J D Talley,Alice Wang,Harlan F. Weisman,Robert M. Califf,Eric J. Topol +9 more
TL;DR: The novel antiplatelet agent c7E3 Fab can be administered during PTCA in combination with aspirin and heparin and can be maintained for up to 24 hours, suggesting suppression of platelet activity is dose dependent.
436
Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus.
TL;DR: The purification procedure included gel filtration on Sephadex G-50, cation-exchange chromatography on Mono S, and C18 reverse-phase high pressure liquid chromatography, and NH2-terminal sequence analysis, and reduction of echistatin abolished its inhibitory activity.
407
Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.
TL;DR: Arteriographically apparent intraluminal thrombus and improvement of the culprit lesion with either of these regimens were only moderately frequent in patients with unstable angina or non-Q wave myocardial infarction, and in two prospectively defined subgroups.
360
References
Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.
M J Davies,A C Thomas +1 more
TL;DR: This controversy was concerned with whether coronary artery thrombi were or were not directly responsible for all three clinical pictures of acute ischaemia.
2.1K
Reactivity of a monoclonal antibody with human ovarian carcinoma.
TL;DR: A murine monoclonal antibody (OC125) has been developed that reacts with each of six epithelial ovarian carcinoma cell lines and with cryopreserved tumor tissue from 12 of 20 ovarian cancer patients, but does not bind to a variety of nonmalignant tissues, including adult and fetal ovary.
Platelet aggregation in partially obstructed vessels and its elimination with aspirin.
J D Folts,E B Crowell,G G Rowe +2 more
TL;DR: Histologic sections of the narrowed coronary artery obtained when coronary flow was reduced show an amorphous mass in the lumen which was thought to be a platelet aggregate, perhaps a similar process of platelet aggregation occurs in the stenosed coronary arteries in man, producing acute coronary obstruction, ischemia, and sudden death.
836
Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
TL;DR: It is concluded that ticlopidine induces a thrombasthenic state in normal platelets without affecting the glycoprotein IIb-IIIa complex quantitatively.